Analysts Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Price Target at $18.67

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has received an average rating of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $18.6667.

A number of equities analysts recently commented on ARTV shares. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday, March 11th. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, January 27th.

Artiva Biotherapeutics Trading Down 3.7%

ARTV stock opened at $11.30 on Tuesday. Artiva Biotherapeutics has a 12 month low of $1.47 and a 12 month high of $14.53. The company has a 50-day moving average price of $6.61 and a 200 day moving average price of $4.91. The stock has a market cap of $279.34 million, a PE ratio of -3.30 and a beta of 1.46.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.03. Sell-side analysts forecast that Artiva Biotherapeutics will post -3.33 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. OMERS ADMINISTRATION Corp bought a new position in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $91,000. Marshall Wace LLP bought a new position in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $341,000. Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $174,000. Renaissance Technologies LLC raised its stake in shares of Artiva Biotherapeutics by 46.8% during the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after acquiring an additional 37,053 shares in the last quarter. Finally, Prelude Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.